US › Healthcare

Cartesian Therapeutics Inc. (RNAC)

US · Healthcare · Biotechnology

$7.53+11.06%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$13.7M

Profit YoY

-13.6%

EPS

$0.46

EPS estimate

$-0.83

EPS came in at 0.46 against a street estimate of -0.83 — a beat of 155.4%.

Key statistics

Market cap

$205.1M

Forward P/E

25.1

P/B

31.26

Book value

$-4.85

EPS (TTM)

$-4.78

52-week high

$11.00

52-week low

$5.60

50-day MA

$7.45

200-day MA

$7.63

Beta

0.76

Analyst view

Analysts rate Cartesian Therapeutics Inc. a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $33.67.

Shareholding

Insiders

52.13%

Institutions

29.45%

Largest institutional holders

Fund	Stake
Squarepoint Ops LLC	7.45%
BlackRock Inc	2.71%
Vanguard Capital Management, LLC	1.84%
FMR Inc	1.22%
Geode Capital Management, LLC	1.18%
AQR Capital Management LLC	1.18%
Millennium Management LLC	1.02%
Two Sigma Investments LLC	0.98%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cartesian Therapeutics Inc. — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.